Horsman M R, Christensen K L, Overgaard J
Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus.
Int J Radiat Oncol Biol Phys. 1992;22(3):455-8. doi: 10.1016/0360-3016(92)90852-9.
The relationship between hydralazine-induced changes in blood pressure and tumor blood flow was investigated in restrained but non-anesthetized CDF1 mice bearing C3H/Tif foot tumors. Mean arterial blood pressure measurements were made using the procedure of carotid cannulation, and tumor blood flow was estimated using laser Doppler flowmetry. Hydralazine doses from 0.1 to 5.0 mg/kg were tested. Following hydralazine administration the maximum changes in blood pressure and blood flow were apparent within 10-15 min and were maintained for at least 30 min after injection. Blood pressure decreased with increasing hydralazine dose, achieving a maximum reduction of 50% at 2.5 mg/kg. Tumor blood flow was found to be increased by 30% at the lowest hydralazine dose (0.1 mg/kg), even though blood pressure was decreased by 10% at this dose. At hydralazine doses producing a 15% or greater blood pressure drop, blood flow decreased, reaching an 80-90% reduction between 2.5 and 5.0 mg/kg.
在患有C3H/Tif足部肿瘤的未麻醉但受到限制的CDF1小鼠中,研究了肼屈嗪引起的血压变化与肿瘤血流之间的关系。采用颈动脉插管法测量平均动脉血压,并用激光多普勒血流仪估计肿瘤血流。测试了0.1至5.0mg/kg的肼屈嗪剂量。给予肼屈嗪后,血压和血流的最大变化在10 - 15分钟内明显,并在注射后至少维持30分钟。血压随肼屈嗪剂量增加而降低,在2.5mg/kg时最大降幅达50%。发现即使在最低肼屈嗪剂量(0.1mg/kg)时血压降低了10%,肿瘤血流仍增加了30%。在产生15%或更大血压下降的肼屈嗪剂量下,血流减少,在2.5至5.0mg/kg之间降至80 - 90%。